aTyr Pharma Posts $7.43 Q3 GAAP Loss Per Share, Expects Resources to Fund Operations Into Late 2028

aTyr Pharma, Inc. (Nasdaq: ATYR) posted a $7.43 per-share GAAP loss for the third quarter and expects its current resources to fund operations into late 2028.

For the quarter ended Sept. 30, the company reported a GAAP loss per share of $7.43.

At Sept. 30, aTyr held $50.3 million in cash, cash equivalents, restricted cash and available-for-sale investments. The company expects that position to support current operations into late 2028, based on its current cash and operating expense outlook and plans.

aTyr also reached alignment with the Food and Drug Administration on a Phase 3 study protocol for efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. Study-related activities have begun, and the company plans to prioritize strategic partnerships to advance the study.